Fuda Cancer Hospital
Fuda Cancer Hospital
China, Guangzhou
Lymphoma treatment cost in China typically ranges from $3,800 to $8,200 for chemotherapy, while advanced CAR T-cell therapy runs $165,000 to $275,000. Total expenses depend on the lymphoma subtype, staging, and choice of hospital tier. Patients often realize 50-70% savings compared to the United States. Top medical destinations include Guangzhou and Beijing.
Typical Lymphoma Treatment Costs in China
Bookimed Expert Insight: Late-stage patients often benefit from multidisciplinary approaches. Fuda Cancer Hospital provides over 10 minimally invasive therapies beyond standard chemotherapy. For high-risk pediatric cases, specialized centers in Beijing like Kyoto Children's Hospital manage complex relapses. JCI-accredited facilities in Guangzhou offer significant experience, serving over 30,000 international patients with advanced technologies like NanoKnife.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Chemotherapy | from $3,800 | from $2,430 | from $2,500 |
| CAR T-cell therapy | from $165,000 | from $150,000 | from $350,000 |
| Bone marrow transplantation | from $55,000 | from $36,000 | from $140,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Lymphoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Lymphoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Lymphoma treatment journey.
Dr. Li Ping, M.D., Ph.D., is Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital, Tongji University School of Medicine. She supervises doctoral and master's students and is an expert in hematologic malignancies.
She earned a Doctor of Medical Science from Nagoya University and completed postdoctoral research. She specializes in diagnosing and treating blood cancers. Her focus includes lymphoid malignancies—leukemias, lymphomas, and multiple myeloma. She treats patients with chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy.
She is a pioneer in China in full-cycle CAR-T therapy for relapsed or refractory blood cancers. She leads and participates in national and international clinical trials. She serves on committees of professional societies, including the China Anti-Cancer Association. She also publishes and trains hematologists.
Written by Anna Leonova
Written by Halina Shubala
China offers advanced lymphoma treatments including CAR T-cell therapy, hematopoietic stem cell transplantation (HSCT), and targeted immunotherapy. Facilities like Lu Daopei Hematology Hospital and Fuda Cancer Hospital follow national protocols. These centers integrate traditional chemotherapy with innovative cellular therapies for relapsed or refractory cases.
Bookimed Expert Insight: Data suggests Beijing is the primary hub for complex hematology. Lu Daopei Hematology Hospital operates 1,300 beds and 30 specialized departments. This massive scale allows for high-volume expertise in stem cell transplants. Patients seeking CAR T-cell therapy can find comprehensive packages at Beijing GoBroad Boren Hospital. These packages often include 30-day hospitalizations to ensure rigorous post-infusion monitoring.
Patient Consensus: Patients note that major Chinese cities offer faster enrollment in clinical trials for relapsed cases. They emphasize that while costs are lower, navigating logistics requires professional support due to language barriers.
Top Chinese hospitals for lymphoma care include JCI-accredited facilities like Fuda Cancer Hospital and specialized hematology centers such as Lu Daopei. These institutions provide advanced CAR-T cell therapy and hematopoietic stem cell transplantation. They serve thousands of international patients with specialized oncology protocols.
Bookimed Expert Insight: While many general hospitals treat lymphoma, specialty centers like Lu Daopei or Boren offer focused hematology infrastructure with 300+ expert doctors. Boren Hospital offers CAR-T therapy packages around $100,000. These include 30 hospital days and extensive diagnostics like biopsies and PET-CT scans.
Patient Consensus: Patients emphasize the need for a bilingual medical liaison to navigate top-tier centers. Many suggest combining local treatment with remote Western second opinions to ensure personalized care protocols.
Lymphoma treatment in China achieves high success at elite centers. Remission rates for Hodgkin lymphoma reach 90% in top-tier facilities. Leading hospitals report success matching global benchmarks for early-stage cases. Advanced therapies like CAR T-cell therapy provide durable responses for aggressive subtypes.
Bookimed Expert Insight: China's top hematology centers offer a massive volume of complex cases. Lu Daopei Hematology Hospital treats 200,000 patients every year. This high patient volume often leads to greater clinical proficiency. Patients can access CAR-T therapy packages at GoBroad Boren Hospital for approximately $100,000. These comprehensive packages include 30 hospital nights and extensive diagnostic testing.
Patient Consensus: Patients note that top-tier hospitals deliver results comparable to Western standards. They emphasize that early detection is vital for the best long-term outcomes.
Traditional Chinese Medicine (TCM) plays a supportive role alongside Western protocols in 90% of Chinese hospitals. It manages chemotherapy side effects like nausea and fatigue for lymphoma patients. Experts use acupuncture and herbal formulas to maintain the body internal balance during intensive treatments.
Bookimed Expert Insight: While TCM is culturally significant, China is currently a global leader in high-tech cellular therapies. Hospitals like Beijing GoBroad Boren Hospital focus heavily on CAR T-cell therapy for lymphoma. This indicates that patients seeking advanced cures should prioritize these specialized hematology centers first. They can then use TCM as a secondary tool for recovery and symptom management.
Patient Consensus: Patients value how TCM helps them feel more balanced during harsh treatments. They note that herbal therapies often make recovery periods between chemotherapy cycles feel more manageable.
Clarify diagnostic accuracy by asking if centers like Fuda Cancer Hospital utilize Joint Commission International (JCI) standards for pathology. Verify if doctors like Dr. Hu Kai perform CAR T-cell therapy under National Medical Products Administration (NMPA) approval. Inquire about exact hospital stay requirements and follow-up protocols.
Bookimed Expert Insight: Lymphoma packages in China, such as those at Beijing GoBroad Boren Hospital, often include 30-day hospitalizations for CAR T-cell therapy. This extended stay is much longer than standard international packages. Patients should confirm if this intensive monitoring is included in the initial $100,000 price or billed separately.
Patient Consensus: Patients emphasize the need for a Mandarin-speaking advocate or an effective translation app like WeChat. They also recommend bringing original pathology slides from home for a second review before starting intensive therapy.
Lymphoma treatment in China requires a stay of 3 to 12 weeks per cycle. Standard chemotherapy often lasts 3 to 6 weeks for monitoring. Advanced CAR-T cell therapy typically necessitates 8 to 12 weeks. This includes preparation, cell manufacturing, and intensive inpatient recovery.
Bookimed Expert Insight: Patients choosing Beijing GoBroad Boren Hospital for CAR-T therapy can expect highly integrated care. Their standard $100,000 package includes a full 30-day hospital stay. This ensures constant monitoring for cytokine release syndrome by specialists like Dr. Hu Kai. This long-term inpatient focus is unique compared to other regions where monitoring is often outpatient.
Patient Consensus: Patients note that arranging a long-term medical visa before arrival is vital. Many advise packing for extended hospital stays as observation periods can unexpectedly increase due to monitoring needs.
Lymphoma treatment in China aligns with Western standards. Most clinics use protocols from the US National Comprehensive Cancer Network. Major hubs like Beijing and Shanghai use identical chemotherapy and PET-CT staging methods. China also leads in CAR T-cell therapy, offering cellular treatments at competitive rates.
Bookimed Expert Insight: Lymphoma care in China is concentrated in specialised haematology centres rather than general hospitals. Beijing GoBroad Boren Hospital offers 30-day inpatient CAR T-cell packages for A$138,000. This extended stay providing more monitoring than many Western outpatient models. This is vital for managing complex responses in relapsed cases.
Patient Consensus: Patients find that top-tier hospitals in China use familiar chemotherapy and molecular testing. They recommend bringing original biopsy material from Australia. This helps doctors align treatment plans with Western pathology standards.
China hosts several hospitals noted for lymphoma care. They focus particularly on CAR T-cell therapy and stem cell transplantation. Beijing GoBroad Boren Hospital and Lu Daopei Hematology Hospital are leading private centres specialising in complex haematology. JCI-accredited Fuda Cancer Hospital in Guangzhou provides specialised oncology protocols for international patients.
Bookimed Expert Insight: Many centres offer lymphoma care. However, Beijing GoBroad Boren Hospital is unique for including a 30-day inpatient stay in its CAR-T packages. This allows for closer monitoring during the critical post-infusion window. This is vital for managing potential side effects safely. Dr Li Ping at Shanghai Tongji Hospital also provides full-cycle CAR-T therapy. This reflects a shift towards integrated care models across major Chinese hubs.
Patient Consensus: Patients emphasise the need for centres with integrated PET/CT imaging and pathology reviews. These help to achieve accurate staging during lymphoma treatment in China. English-speaking support is also an essential factor for navigating these large, highly specialised haematology facilities.
China is a top destination for CAR-T therapy for lymphoma. Specialist hubs in Beijing, Shanghai, and Guangzhou offer commercial treatments and extensive clinical trials. Leading facilities like Beijing GoBroad Boren Hospital and JCI-accredited Fuda Cancer Hospital provide structured programmes for relapsed or refractory cases.
Bookimed Expert Insight: Clinical data shows Beijing focuses heavily on haematology infrastructure. Hospitals there often bundle 30 days of inpatient monitoring into CAR-T packages. This long stay is vital for managing cytokine release syndrome. Choosing a specialist haematology hospital provides 24-hour access to expert blood cancer teams.
Patient Consensus: Patients note that CAR-T treatment in China is concentrated in major tertiary hospitals. Extensive disease profiling and English-translated records are essential for Australian patients seeking hospital acceptance.
Australian patients can find quality lymphoma treatment in China by choosing JCI-accredited facilities with many international patients. Verify specialist credentials and access to therapies like CAR T-cell therapy. Leading centres like Fuda Cancer Hospital in Guangzhou maintain global safety standards.
Bookimed Expert Insight: Lymphoma patients should prioritise centres specialising in haematology rather than general hospitals. Beijing GoBroad Boren Hospital focuses entirely on blood disorders. This focus often provides deeper experience with CAR-T and bone marrow transplants.
Patient Consensus: Patients value hospitals with clear communication about pathology reviews and quick PET-CT scan access. Experiences in China highlight the need to verify that the team understands the chemotherapy protocol.
Lymphoma treatment in China routinely combines Traditional Chinese Medicine (TCM) with Western therapies. Doctors use TCM to manage chemotherapy side effects and support the immune system. This integrated approach is common across major oncology centres in Beijing and Guangzhou.
Bookimed Expert Insight: While Chinese centres are famous for TCM, our data shows they actually lead in Western techniques. Beijing GoBroad Boren Hospital and Shanghai Tongji Hospital focus on full-cycle CAR T-cell therapy and stem cell transplants. For Australian patients, TCM is usually a complementary add-on rather than the primary treatment focus.
Chinese hospitals provide dedicated international patient centres to manage language and logistics for lymphoma treatment. Facilities like Fuda Cancer Hospital hold JCI accreditation. They also offer therapies such as CAR-T and bone marrow transplants. Support often includes translation services and visa assistance.
Bookimed Expert Insight: China has emerged as a major hub for CAR-T cell therapy for lymphoma. Specialists like Dr Li Ping at Shanghai Tongji Hospital lead international clinical trials. Packages like the CAR-T protocol at Beijing GoBroad Boren Hospital cost around A$138,000. These provide long 30-day hospitalisations. This level of inpatient monitoring is rare elsewhere. It helps keep patients safe during the critical immune-response phase.
Patient Consensus: International patients note that Chinese oncology centres are highly experienced in treating late-stage cases. They treat patients from over 100 countries. Many patients appreciate staff who understand the logistical needs of foreign families.